Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Breast Cancer, Lung Cancer, GI Cancer
Interventions: Pharmacy Intervention, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hiv, Fatigue, Mobility Limitation
Interventions: HIIT (intervention), CME (active control), Coaching, Control text message; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Neoplasms
Interventions: AB0024; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Detroit, Michigan • San Antonio, Texas

Conditions: Epithelial Ovarian Cancer
Interventions: Intermittent Fasting, Neoadjuvant chemotherapy; Behavioral · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adverse Drug Interactions
Interventions: Rifampicin, sulforaphane plus rifampicin, sulforaphane alone; Drug · Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Oncology
Interventions: BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg), BAY94-9343 (2.2 mg/kg); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 8
States / cities: New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more

Conditions: Healthy
Interventions: ACT-1004-1239, Placebo, ACT-1004-1239 (Food-effect subpart), Placebo (Food-effect subpart); Drug · Other
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neoplasms, Tumor
Interventions: IMC-TR1; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas • San Antonio, Texas

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Lumbar puncture, Blood draw, Magnetic Resonance Imaging (MRI); Procedure
Lead sponsor: Emory University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Vasomotor Symptoms, Menopausal Symptoms
Interventions: Estetrol, Placebo, Progesterone; Drug
Lead sponsor: Estetra; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 65
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more

Conditions: Obesity
Interventions: Lesson about vegetables, Vegetables, Hummus; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Months to 24 Months
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Columbus, Ohio • San Antonio, Texas

Conditions: Muckle Wells Syndrome
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 4 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Madison, Wisconsin

Conditions: Sarcoma, Soft Tissue
Interventions: Olaratumab, Doxorubicin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: COVID-19
Interventions: Licensed or EUA SARS-CoV-2 vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more

Conditions: AML, MDS
Interventions: NKR-2; Biological
Lead sponsor: Celyad Oncology SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 1 more

Conditions: Neoplasms, Germ Cell and Embryonal
Interventions: Next generation genome sequencing; Genetic
Lead sponsor: Nasser Hanna; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Microbiota, Gut Microbiome, Eczema, Microbiome
Interventions: Tailored Recommendations, Consult Call, Educational Email Series; Dietary Supplement · Behavioral
Lead sponsor: Seeding Inc; Industry
Eligibility: 0 Months to 3 Months
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Cullman, Alabama • Maitland, Florida • Tampa, Florida + 5 more

Conditions: Autism Spectrum Disorder
Interventions: Reciprocal Imitation Training; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 16 Months to 33 Months
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • East Lansing, Michigan + 1 more

Conditions: Smoking Cessation
Interventions: Nicotine Mini-Lozenge for 11 Months, Preparation Phase Behavioral Reduction Counseling, Preparation Phase Recycling Counseling, Preparation Phase Control Treatment, Cessation Phase Supportive Counseling, Cessation Phase Skill Training Counseling, Cessation Phase Brief Information, Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge; Drug · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystic Fibrosis
Interventions: RCT2100, Placebo, Ivacaftor; Drug · Other
Lead sponsor: ReCode Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 10 more

Conditions: Secondary School Student in General High School Who Does Not Have a Disability That Does Not Allow a Good Understanding of the Study Requirements
Interventions: Impulsive intervention, Reflective Intervention; Behavioral
Lead sponsor: Institut de Cancérologie de la Loire; Other
Eligibility: 15 Years to 19 Years
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Washington, Massachusetts

Conditions: Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Talazoparib, Tazemetostat; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

A Study of IMC-TR1 in Participants With Advanced Solid Tumors

African American Alzheimer's Progression Markers - CSF and Neuro-Imaging

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Hummus for Health: Dietary Quality and Health Outcomes in Toddlers

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

Multisite Observational Maternal and Infant Study for COVID-19

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse

Flourish: Exploring the Early Infant Gut Microbiome

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

Improving the Part C Early Intervention Service Delivery System for Children With ASD

The Long-Term Quitting (Smoking Cessation) Study

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

I2S-Health Prevention

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC